Bristol-Myers Immunotherapy Opdivo Shows Promising Results In The Treatment Of Advanced Melanoma
News
During the Society for Melanoma Research 2014 International Congress in Zurich, Switzerland, Bristol-Myers Squibb (BMS) presented the results of its CheckMate-066 trial, a Phase 3 randomized, double-blind study comparing Opdivo (nivolumab) to ... Read more